Home › Carcinoma uroteliale (a cellule transizionali) › New York
Studi clinici su Carcinoma uroteliale (a cellule transizionali) nello stato di New York
29 studi su Carcinoma uroteliale (a cellule transizionali) cercano partecipanti presso sedi nello stato di New York.
Città nello stato di New York
- New York City22 studi
- Queens15 studi
- New Rochelle7 studi
- Staten Island7 studi
- Greenburgh7 studi
- Rochester3 studi
- Syracuse3 studi
- Albany3 studi
Testo ufficiale dello studio (inglese)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New York Long Island LLC, Lake Success
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
- Exelixis Clinical Site #76, Syracuse
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- Roswell Park Cancer Institute, Buffalo
- Stony Brook University Medical Center, Stony Brook
- Roswell Park Amherst Center, Williamsville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06524544Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- e altri 3
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- The Feinstein Institutes for Medical Research, Lake Success
- NYU Grossman School of Medicine, New York
- SUNY Upstate, Syracuse
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT05874921DBC-664 in Adult Patients With Solid Tumors
- START New York, Lake Success
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07705035A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- Memorial Sloan Kettering Cancer Center ( Site 1031), New York
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05562830Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- New York Oncology Hematology, Albany
- New York Oncology Hematology, Clifton Park
- Icahn School of Medicine at Mount Sinai, New York
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Columbia University Irving Medical Center, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277413A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07218380Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT06439836Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- Memorial Sloan Kettering -Nassau, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT05239624A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07532902GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT04977453A Study of GEN1106 in Participants With Solid Tumors
- START New York Long Island LLC, Lake Success
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT07416123Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- University of Rochester Medical Center, Rochester
- Montefiore Medical Center - Bronx, The Bronx
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06774131A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- START New York Long Island, New Hyde Park
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT07287995Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- New York Cancer & Blood Specialists, New York
- University of Rochester - Wilmot Cancer Institute, Rochester
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06582017A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- e altri 1
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06330064An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Albany
- Research Site, New York
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- MSK Commack, Commack
- MSK Wesrchester, Harrison
- Memorial Sloan Kattering Cancer Centre- Investigational Drug Service Pharmacy, Long Island City
- e altri 6
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT04879329A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 lug 2026 · NCT06695845Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Albany MED Health System, Albany
- Integrated Medical Professionals, New York
- Premier Medical Group of the Hudson Valley, P. C., Poughkeepsie
In reclutamento
Età da 18 a 88 · Tutti i sessi · Aggiornato il 2 lug 2026 · NCT06394869Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
- Start New York, LLC, Lake Success
- MSK, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 giu 2026 · NCT07484022A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- e altri 1
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT07390617A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT05562791Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
- Site 02-015 - Associated Medical Professionals of New York, Syracuse
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 nov 2025 · NCT03945162SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- e altri 2
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.